专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100266643A1 PULMONARY AND NASAL DELIVERY OF SERUM AMYLOID P 审中-公开
标题翻译：血清淀粉酶的脉冲和鼻腔递送
公开(公告)号：US20100266643A1
公开(公告)日：2010-10-21
申请号：US12752627
申请日：2010-04-01
申请人： W. Scott Willett , Richard J. Caimi , Lynne Anne Murray
发明人： W. Scott Willett , Richard J. Caimi , Lynne Anne Murray
IPC分类号： A61K38/16 , A61K9/14 , A61P11/00
CPC分类号： A61K38/1716 , A61K9/0043 , A61K9/0078
摘要： The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided.
摘要翻译：本公开涉及将血清淀粉样蛋白P递送至呼吸系统的方法。还提供了包含适合于呼吸递送的SAP的药物组合物。

2. 发明申请

US20130064866A1 PULMONARY AND NASAL DELIVERY OF SERUM AMYLOID P 审中-公开
标题翻译：血清淀粉酶的脉冲和鼻腔递送
公开(公告)号：US20130064866A1
公开(公告)日：2013-03-14
申请号：US13607240
申请日：2012-09-07
申请人： W. Scott Willett , Richard J. Caimi , Lynne Anne Murray
发明人： W. Scott Willett , Richard J. Caimi , Lynne Anne Murray
IPC分类号： A61K38/17 , A61M15/00 , A61P11/00 , C07K14/435 , A61K9/14
CPC分类号： A61K38/1716 , A61K9/0043 , A61K9/0078
摘要： The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided.
摘要翻译：本公开涉及将血清淀粉样蛋白P递送至呼吸系统的方法。还提供了包含适合于呼吸递送的SAP的药物组合物。

3. 发明申请

US20100323970A1 SAP VARIANTS AND THEIR USE 有权
标题翻译： SAP变量及其使用
公开(公告)号：US20100323970A1
公开(公告)日：2010-12-23
申请号：US12817535
申请日：2010-06-17
申请人： W. Scott Willett
发明人： W. Scott Willett
IPC分类号： A61K38/17 , C07K14/435 , A61P29/00 , A61P37/00 , A61P27/00 , A61P35/00
CPC分类号： C07K14/4711 , A61K38/00 , A61K38/17
摘要： Polypeptides are susceptible to denaturation or enzymatic degradation in the blood, liver or kidney. Due to the low stability of some polypeptides, it has been required to administer polypeptide drugs in a sustained frequency to a subject in order to maintain an effective plasma concentration of the active substance. Furthermore, pharmaceutical compositions of therapeutic peptides preferably have a shelf-life of several years in order to be suitable for common use. However, peptide compositions are inherently unstable due to sensitivity towards chemical and physical degradation. In part, the invention provides SAP variant proteins, compositions, pharmaceutical preparations and formulations having a prolonged in vivo half-life, prolonged shelf-life, or rather increased in vitro stability, or increased manufacturing efficiency compared to human SAP. Advantages of increased plasma half-life include, but are not limited to, reducing the amount and/or frequency of dosing.
摘要翻译：多肽易受血液，肝脏或肾脏变性或酶降解的影响。由于某些多肽的稳定性低，为了维持活性物质的有效血浆浓度，需要以持续的频率向受试者施用多肽药物。此外，治疗性肽的药物组合物优选具有几年的保质期以适合于常用。然而，由于对化学和物理降解的敏感性，肽组合物本质上是不稳定的。部分地，本发明提供SAP变体蛋白质，组合物，药物制剂和具有延长的体内半衰期，延长的保质期或相当于体外稳定性提高的制剂或与人SAP相比提高的制造效率。增加血浆半衰期的优点包括但不限于减少给药量和/或剂量的频率。

4. 发明授权

US5202239A Expression of recombinant polypeptides with improved purification 失效
标题翻译：用改进的纯化表达重组多肽
公开(公告)号：US5202239A
公开(公告)日：1993-04-13
申请号：US564259
申请日：1990-08-07
申请人： S. Joseph Tarnowski , Sandra Hilliker , W. Scott Willett
发明人： S. Joseph Tarnowski , Sandra Hilliker , W. Scott Willett
IPC分类号： C07K14/52 , C07K14/00 , C07K14/575 , C07K14/58 , C07K14/585 , C07K14/60 , C07K14/62 , C07K14/655 , C07K19/00 , C12N1/21 , C12N15/02 , C12N15/09 , C12N15/62 , C12P21/02 , C12R1/19
CPC分类号： C07K14/58 , C12N15/625 , C07K2319/02 , C07K2319/50 , C07K2319/61 , C07K2319/75
摘要： An improved method for expressing peptides as fusion proteins, uses a carrier for a heterologous peptide to provide a fusion protein having a high pI. The high isoelectric point facilitates separation of the fusion protein from all other host cell proteins, and separation of the carrier from the peptide after cleavage.
摘要翻译：用于表达肽作为融合蛋白的改进方法使用异源肽的载体提供具有高pI的融合蛋白。高等电点有助于融合蛋白与所有其他宿主细胞蛋白的分离，以及切割后载体与肽的分离。

5. 发明授权

US09296800B2 Serum amyloid P derivatives and their preparation and use 有权
标题翻译：血清淀粉样蛋白衍生物及其制备及应用
公开(公告)号：US09296800B2
公开(公告)日：2016-03-29
申请号：US12794132
申请日：2010-06-04
申请人： W. Scott Willett , Richard J. Caimi
发明人： W. Scott Willett , Richard J. Caimi
IPC分类号： C07K14/47 , A61K38/00
CPC分类号： C07K14/47 , A61K38/00
摘要： One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.
摘要翻译：本发明的一个方面涉及令人惊奇的发现，即在人SAP多肽上修饰聚糖结构可以相对于从人血清分离的野生型SAP的相应样品增加SAP多肽的生物学活性。本公开提供了两种变体人SAP多肽及其制备方法。特别地，本发明提供了用于体外和体内添加，缺失或修饰糖残基以产生具有所需糖基化模式的SAP多肽（例如人SAP多肽）的方法和组合物。

6. 发明授权

US08329659B2 SAP variants and their use 有权
标题翻译： SAP变体及其用途
公开(公告)号：US08329659B2
公开(公告)日：2012-12-11
申请号：US12817535
申请日：2010-06-17
申请人： W. Scott Willett
发明人： W. Scott Willett
IPC分类号： A61K38/16 , A61K38/00 , C07K14/00 , C07K17/00
CPC分类号： C07K14/4711 , A61K38/00 , A61K38/17
摘要： Polypeptides are susceptible to denaturation or enzymatic degradation in the blood, liver or kidney. Due to the low stability of some polypeptides, it has been required to administer polypeptide drugs in a sustained frequency to a subject in order to maintain an effective plasma concentration of the active substance. Furthermore, pharmaceutical compositions of therapeutic peptides preferably have a shelf-life of several years in order to be suitable for common use. However, peptide compositions are inherently unstable due to sensitivity towards chemical and physical degradation. In part, the invention provides SAP variant proteins, compositions, pharmaceutical preparations and formulations having a prolonged in vivo half-life, prolonged shelf-life, or rather increased in vitro stability, or increased manufacturing efficiency compared to human SAP. Advantages of increased plasma half-life include, but are not limited to, reducing the amount and/or frequency of dosing.
摘要翻译：多肽易受血液，肝脏或肾脏变性或酶降解的影响。由于某些多肽的稳定性低，为了维持活性物质的有效血浆浓度，需要以持续的频率向受试者施用多肽药物。此外，治疗性肽的药物组合物优选具有几年的保质期以适合于常用。然而，由于对化学和物理降解的敏感性，肽组合物本质上是不稳定的。部分地，本发明提供SAP变体蛋白质，组合物，药物制剂和具有延长的体内半衰期，延长的保质期或相当于体外稳定性提高的制剂或与人SAP相比提高的制造效率。增加血浆半衰期的优点包括但不限于减少给药量和/或剂量的频率。

7. 发明申请

US20100317596A1 SERUM AMYLOID P DERIVATIVES AND THEIR PREPARATION AND USE 有权
标题翻译： SERUM AMYLOID P衍生物及其制备和使用
公开(公告)号：US20100317596A1
公开(公告)日：2010-12-16
申请号：US12794132
申请日：2010-06-04
申请人： W. Scott Willett , Richard J. Caimi
发明人： W. Scott Willett , Richard J. Caimi
IPC分类号： A61K38/14 , C07K9/00 , C12P21/00 , C12N5/10 , A61P37/00
CPC分类号： C07K14/47 , A61K38/00
摘要： One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.
摘要翻译：本发明的一个方面涉及令人惊奇的发现，即在人SAP多肽上修饰聚糖结构可以相对于从人血清分离的野生型SAP的相应样品增加SAP多肽的生物学活性。本公开提供了两种变体人SAP多肽及其制备方法。特别地，本发明提供了用于体外和体内添加，缺失或修饰糖残基以产生具有所需糖基化图案的SAP多肽（例如人SAP多肽）的方法和组合物。

8. 发明授权

US5322930A Expression of recombinant polypeptides with improved purification 失效
标题翻译：改良纯化重组多肽的表达
公开(公告)号：US5322930A
公开(公告)日：1994-06-21
申请号：US974932
申请日：1992-11-12
申请人： S. Joseph Tarnowski , Sandra Hilliker , W. Scott Willett
发明人： S. Joseph Tarnowski , Sandra Hilliker , W. Scott Willett
IPC分类号： C07K14/52 , C07K14/00 , C07K14/575 , C07K14/58 , C07K14/585 , C07K14/60 , C07K14/62 , C07K14/655 , C07K19/00 , C12N1/21 , C12N15/02 , C12N15/09 , C12N15/62 , C12P21/02 , C12R1/19 , C07K13/00
CPC分类号： C07K14/58 , C12N15/625 , C07K2319/02 , C07K2319/50 , C07K2319/61 , C07K2319/75
摘要： An improved method for expressing peptides as fusion proteins, uses a carrier for a heterologous peptide to provide a fusion protein having a high pI. The high isoelectric point facilitates separation of the fusion protein from all other host cell proteins, and separation of the carrier from the peptide after cleavage.
摘要翻译：用于表达肽作为融合蛋白的改进方法使用异源肽的载体提供具有高pI的融合蛋白。高等电点有助于融合蛋白与所有其他宿主细胞蛋白的分离，以及切割后载体与肽的分离。

9. 发明申请

US20100113743A1 GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA 审中-公开
标题翻译：糖蛋白因子VII和因子VIIA
公开(公告)号：US20100113743A1
公开(公告)日：2010-05-06
申请号：US12605041
申请日：2009-10-23
申请人： Shawn DeFrees , David A. Zopf , Susann Taudte , W. Scott Willett , Matthew Kalo , Robert J. Bayer
发明人： Shawn DeFrees , David A. Zopf , Susann Taudte , W. Scott Willett , Matthew Kalo , Robert J. Bayer
IPC分类号： C07K14/745
CPC分类号： C07K14/745 , A61K47/549 , A61K47/60
摘要： The present invention provides conjugates between Factor VII or Factor VIIa peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.
摘要翻译：本发明提供因子VII或因子VIIa肽和PEG部分之间的缀合物。缀合物经由完整的糖基连接基团连接，该基团介于并共价连接到肽和修饰基团之间。通过糖基转移酶的作用，缀合物由糖基化和未糖基化的肽形成。糖基转移酶将修饰的糖部分连接到肽上的氨基酸或糖基残基上。还提供了包括缀合物的药物制剂。缀合物的制备方法也在本发明的范围内。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式